Skip to content

HCG (Human Chorionic Gonadotropin) Priming for Thin Endometrium in IVF (in Vitro Fertilization)

HCG Priming for Thin Endometrium in IVF

Status
UNKNOWN
Phases
Phase 4
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT01768247
Enrollment
15
Registered
2013-01-15
Start date
2012-01-31
Completion date
2014-01-31
Last updated
2013-01-17

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Endometrial Thickness, Pregnancy Outcome

Keywords

endometrium, thickness, pregnancy, HCG, frozen cycles

Brief summary

A thin endometrium is one of the most difficult problems encountered in assisted reproduction every day practice Regarding the proliferative phase, several ways of treatment have been undertaken to circumvent thin endometrium trying to increase thickness with questionable results. The objective of the current study will be whether a daily dose of 150 IU (international units) of human chorionic gonadotropin (HCG) for seven days concomitant with estrogen administration in estrogen replacement cycles can increase the endometrial thickness and improve pregnancy outcome.

Detailed description

In this pilot study subjects with repeatedly resistant thin endometrium, less than 6mm, will be recruited. The investigators sought to investigate the possible role of adding low dose HCG in the follicular phase, on the endometrial growth and development. The investigators constructed this hypothesis based on the fact that LH/HCG (luteinizing hormone/human chorionic gonadotropin) receptor is present in endometrium and therefore a positive interaction could be anticipated when HCG is administered in the proliferative phase of endometrial growth. Furthermore, in a previous study, where human menopausal gonadotropin (hMG) -well known that renders its luteinizing hormone (LH) capacity due to low dose HCG contain- was compared to recombinant-follicular stimulating hormone (rec-FSH) during ovarian stimulation, endometrium was more likely to be iso-echogenic and hypo-echogenic in the hMG group, also anticipating a possible positive role of HCG activity.

Interventions

150 international units (IU) of HCG for seven days subcutaneously concomitantly with estrogens in preparation endometrium cycles fro frozen embryos replacement

Sponsors

Human Reproduction & Genetics Foundation
CollaboratorUNKNOWN
Universitair Ziekenhuis Brussel
Lead SponsorOTHER

Study design

Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE

Eligibility

Sex/Gender
FEMALE
Age
30 Years to 50 Years
Healthy volunteers
No

Inclusion criteria

* (1) Less than 6mm endometrial thickness before, (2) at least two failed implantations before

Exclusion criteria

* Abnormal uterine cavity in Hysteroscopy

Design outcomes

Primary

MeasureTime frameDescription
Endometrial thickness14 days after estrogen treatmentmeasured by transvaginal ultrasound

Secondary

MeasureTime frameDescription
Pregnancy outcome5 weeks after embryotransferClinical pregnancy

Countries

Greece

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Mar 22, 2026